Immuneering Corporation Class A Common Stock IMRX
i
Market datapartial · fetched 2026-11-12T03:04:02.749Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T00:50:04.514568169Z
FundamentalsAlpha Vantage · unavailable
Immuneering Corporation Class A Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 2.63 | 232.7% | 43.3% | |||
| 25Δ | 2.84 | 220.4% | 39.7% | |||
| 30Δ | 3.05 | 208.0% | 36.1% | |||
| 35Δ | 4.87 | 118.9% | 34.5% | 3.26 | 195.7% | 32.5% |
| 40Δ | 4.68 | 115.8% | 31.8% | 3.48 | 183.4% | 29.0% |
| 45Δ | 4.48 | 112.8% | 29.0% | 3.69 | 171.0% | 25.4% |
| 50Δ | 4.29 | 109.7% | 26.3% | 3.90 | 158.7% | 21.8% |
| 55Δ | 4.10 | 106.7% | 23.5% | 4.12 | 146.3% | 18.2% |
| 60Δ | 3.91 | 103.6% | 20.7% | 4.33 | 134.0% | 14.6% |
| 65Δ | 3.71 | 100.6% | 18.0% | 4.54 | 121.7% | 11.0% |
| 70Δ | 3.52 | 97.6% | 15.2% | 4.75 | 109.3% | 7.4% |
| 75Δ | 3.33 | 94.5% | 12.5% | 4.97 | 97.0% | 3.8% |
| 80Δ | 3.14 | 91.5% | 9.7% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.63
- IV
- 232.7%
- B/E move
- 43.3%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.84
- IV
- 220.4%
- B/E move
- 39.7%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.05
- IV
- 208.0%
- B/E move
- 36.1%
35Δ
- Pseudo strike
- 4.87
- IV
- 118.9%
- B/E move
- 34.5%
- Pseudo strike
- 3.26
- IV
- 195.7%
- B/E move
- 32.5%
40Δ
- Pseudo strike
- 4.68
- IV
- 115.8%
- B/E move
- 31.8%
- Pseudo strike
- 3.48
- IV
- 183.4%
- B/E move
- 29.0%
45Δ
- Pseudo strike
- 4.48
- IV
- 112.8%
- B/E move
- 29.0%
- Pseudo strike
- 3.69
- IV
- 171.0%
- B/E move
- 25.4%
50Δ
- Pseudo strike
- 4.29
- IV
- 109.7%
- B/E move
- 26.3%
- Pseudo strike
- 3.90
- IV
- 158.7%
- B/E move
- 21.8%
55Δ
- Pseudo strike
- 4.10
- IV
- 106.7%
- B/E move
- 23.5%
- Pseudo strike
- 4.12
- IV
- 146.3%
- B/E move
- 18.2%
60Δ
- Pseudo strike
- 3.91
- IV
- 103.6%
- B/E move
- 20.7%
- Pseudo strike
- 4.33
- IV
- 134.0%
- B/E move
- 14.6%
65Δ
- Pseudo strike
- 3.71
- IV
- 100.6%
- B/E move
- 18.0%
- Pseudo strike
- 4.54
- IV
- 121.7%
- B/E move
- 11.0%
70Δ
- Pseudo strike
- 3.52
- IV
- 97.6%
- B/E move
- 15.2%
- Pseudo strike
- 4.75
- IV
- 109.3%
- B/E move
- 7.4%
75Δ
- Pseudo strike
- 3.33
- IV
- 94.5%
- B/E move
- 12.5%
- Pseudo strike
- 4.97
- IV
- 97.0%
- B/E move
- 3.8%
80Δ
- Pseudo strike
- 3.14
- IV
- 91.5%
- B/E move
- 9.7%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 112.76% | |
| 97.16% | |
| 102.27% | |
| 90.25% |
Biotechnology
IMTX
Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor (TCR) -based immunotherapies for the treatment of cancer in…
More →IMUX
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a line of selective oral immunology therapies for the treatment of chronic autoimmune and inflammatory…
More →IMVT
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company is headquartered in New York,…
More →INBX
Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. The company is headquartered in La Jolla,…
More →INCY
Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.
More →INMB
Description unavailable
More →